Characterization and optimization of orodispersible mosapride film formulations.
Orodispersible film (ODF) technology offers new possibilities for drug delivery by providing the advantages of oral delivery coupled with the enhanced onset of action and convenience to special patient categories such as pediatrics and geriatrics. In this study, mosapride (MOS) was formulated in an ODF preparation that can be used for treatment of patients who suffer from gastrointestinal disorders, especially difficulty in swallowing due to gastroesophageal reflux disease. Poloxamer 188 was used to solubilize MOS to allow its incorporation into the film matrix. The films were prepared by solvent-casting method using different polymer ratios of maltodextrin and hydroxypropyl methylcellulose and plasticizer levels of glycerol and propylene glycol. A D-optimal design was utilized to study the effect of polymer ratio, plasticizer type, and level on film mechanical properties, disintegration time, and dissolution rate. Statistical analysis of the experimental design showed that the increase of maltodextrin fraction and plasticizer level conferred optimum attributes to the prepared films in terms of film elasticity, film disintegration time, and MOS release rate. The ODF formulations were further tested for moisture sorption capacity, with formulations containing a higher ratio of maltodextrin and percent plasticizer showing more moisture uptake. The optimum film composition was also tested in vivo for film palatability and disintegration time. An optimized mosapride orodispersible film formulation was achieved that could be of benefit to patients suffering from gastrointestinal disorders.
Department of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, Cairo University, Egypt.
Aliaa N
AN
ElMeshad
Arwa S
AS
El Hagrasy
D000284:Administration, Oral; D000328:Adult; D001549:Benzamides / Q000008:administration & dosage* / Q000009:adverse effects / Q000737:chemistry; D002626:Chemistry, Pharmaceutical; D004304:Dosage Forms; D004337:Drug Carriers; D004339:Drug Compounding; D004548:Elasticity; D005260:Female; D005765:Gastrointestinal Agents / Q000008:administration & dosage* / Q000009:adverse effects / Q000737:chemistry; D005990:Glycerol / Q000737:chemistry; D006801:Humans; D065347:Hypromellose Derivatives; D007700:Kinetics; D008297:Male; D008747:Methylcellulose / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000737:chemistry; D015233:Models, Statistical; D009025:Morpholines / Q000008:administration & dosage* / Q000009:adverse effects / Q000737:chemistry; D017060:Patient Satisfaction; D010968:Plasticizers / Q000737:chemistry; D020442:Poloxamer / Q000737:chemistry; D011134:Polysaccharides / Q000009:adverse effects / Q000737:chemistry*; D019946:Propylene Glycol / Q000737:chemistry; D012677:Sensation; D012995:Solubility; D013678:Technology, Pharmaceutical / Q000379:methods; D014867:Water / Q000737:chemistry
D001549:Benzamides; D004304:Dosage Forms; D004337:Drug Carriers; D005765:Gastrointestinal Agents; D009025:Morpholines; D010968:Plasticizers; D011134:Polysaccharides; D014867:Water; D020442:Poloxamer; D065347:Hypromellose Derivatives; D019946:Propylene Glycol; C008315:maltodextrin; D008747:Methylcellulose; C062720:mosapride; D005990:Glycerol